153 related articles for article (PubMed ID: 30676789)
1. Impact of Medicaid Restrictions on Availability of Buprenorphine in Addiction Treatment Programs.
Andrews CM; Abraham AJ; Grogan CM; Westlake MA; Pollack HA; Friedmann PD
Am J Public Health; 2019 Mar; 109(3):434-436. PubMed ID: 30676789
[TBL] [Abstract][Full Text] [Related]
2. Medicaid Managed Care Prior Authorization For Buprenorphine Tied To State Partisanship And Health Plan Profit Status, 2018.
Andrews CM; Westlake MA; Abraham AJ; Grogan CM; Harris SJ; Jehan S
Health Aff (Millwood); 2024 Jan; 43(1):55-63. PubMed ID: 38190595
[TBL] [Abstract][Full Text] [Related]
3. The impact of prior authorization on buprenorphine dose, relapse rates, and cost for Massachusetts Medicaid beneficiaries with opioid dependence.
Clark RE; Baxter JD; Barton BA; Aweh G; O'Connell E; Fisher WH
Health Serv Res; 2014 Dec; 49(6):1964-79. PubMed ID: 25040021
[TBL] [Abstract][Full Text] [Related]
4. Buprenorphine Treatment For Opioid Use Disorder: Comparison Of Insurance Restrictions, 2017-21.
Andraka-Christou B; Simon KI; Bradford WD; Nguyen T
Health Aff (Millwood); 2023 May; 42(5):658-664. PubMed ID: 37126752
[TBL] [Abstract][Full Text] [Related]
5. Thematic Analysis of State Medicaid Buprenorphine Prior Authorization Requirements.
Nguemeni Tiako MJ; Dolan A; Abrams M; Oyekanmi K; Meisel Z; Aronowitz SV
JAMA Netw Open; 2023 Jun; 6(6):e2318487. PubMed ID: 37318805
[TBL] [Abstract][Full Text] [Related]
6. Buprenorphine Use Trends Following Removal of Prior Authorization Policies for the Treatment of Opioid Use Disorder in 2 State Medicaid Programs.
Keshwani S; Maguire M; Goodin A; Lo-Ciganic WH; Wilson DL; Hincapie-Castillo JM
JAMA Health Forum; 2022 Jun; 3(6):e221757. PubMed ID: 35977240
[TBL] [Abstract][Full Text] [Related]
7. Opioid drugs in maintenance and detoxification treatment of opiate addiction; proposed modification of dispensing restrictions for buprenorphine and buprenorphine combination as used in approved opioid treatment medications. Final rule.
Substance Abuse and Mental Health Services Administration (SAMHSA), Department of Health and Human Services (HHS)
Fed Regist; 2012 Dec; 77(235):72752-61. PubMed ID: 23227572
[TBL] [Abstract][Full Text] [Related]
8. Responses among substance abuse treatment providers to the opioid epidemic in the USA: Variations in buprenorphine and methadone treatment by geography, operational, and payment characteristics, 2007-16.
Yang JC; Roman-Urrestarazu A; Brayne C
PLoS One; 2020; 15(3):e0229787. PubMed ID: 32126120
[TBL] [Abstract][Full Text] [Related]
9. How do state Medicaid programs determine what substance use disorder treatment medications need prior authorization? An overview for clinicians.
Bachhuber MA
Addict Sci Clin Pract; 2020 Jun; 15(1):20. PubMed ID: 32600402
[TBL] [Abstract][Full Text] [Related]
10. Buprenorphine treatment episode duration, dosage, and concurrent prescribing of benzodiazepines and opioid analgesics: The effects of Medicaid prior authorization policies.
Landis RK; Opper I; Saloner B; Gordon AJ; Leslie DL; Sorbero M; Stein BD
Drug Alcohol Depend; 2022 Dec; 241():109669. PubMed ID: 36332589
[TBL] [Abstract][Full Text] [Related]
11. Policies related to opioid agonist therapy for opioid use disorders: The evolution of state policies from 2004 to 2013.
Burns RM; Pacula RL; Bauhoff S; Gordon AJ; Hendrikson H; Leslie DL; Stein BD
Subst Abus; 2016; 37(1):63-9. PubMed ID: 26566761
[TBL] [Abstract][Full Text] [Related]
12. Financial factors and the implementation of medications for treating opioid use disorders.
Knudsen HK; Roman PM
J Addict Med; 2012 Dec; 6(4):280-6. PubMed ID: 22810057
[TBL] [Abstract][Full Text] [Related]
13. Risk Factors for Relapse and Higher Costs Among Medicaid Members with Opioid Dependence or Abuse: Opioid Agonists, Comorbidities, and Treatment History.
Clark RE; Baxter JD; Aweh G; O'Connell E; Fisher WH; Barton BA
J Subst Abuse Treat; 2015 Oct; 57():75-80. PubMed ID: 25997674
[TBL] [Abstract][Full Text] [Related]
14. Association of Buprenorphine-Waivered Physician Supply With Buprenorphine Treatment Use and Prescription Opioid Use in Medicaid Enrollees.
Wen H; Hockenberry JM; Pollack HA
JAMA Netw Open; 2018 Sep; 1(5):e182943. PubMed ID: 30646185
[TBL] [Abstract][Full Text] [Related]
15. State policy influence on the early diffusion of buprenorphine in community treatment programs.
Ducharme LJ; Abraham AJ
Subst Abuse Treat Prev Policy; 2008 Jun; 3():17. PubMed ID: 18570665
[TBL] [Abstract][Full Text] [Related]
16. Impact of Medicaid Expansion on Medicaid-covered Utilization of Buprenorphine for Opioid Use Disorder Treatment.
Wen H; Hockenberry JM; Borders TF; Druss BG
Med Care; 2017 Apr; 55(4):336-341. PubMed ID: 28296674
[TBL] [Abstract][Full Text] [Related]
17. Buprenorphine prescribing for opioid use disorder in medical practices: can office-based out-patient care address the opiate crisis in the United States?
Rhee TG; Rosenheck RA
Addiction; 2019 Nov; 114(11):1992-1999. PubMed ID: 31307111
[TBL] [Abstract][Full Text] [Related]
18. Rise and regional disparities in buprenorphine utilization in the United States.
Pashmineh Azar AR; Cruz-Mullane A; Podd JC; Lam WS; Kaleem SH; Lockard LB; Mandel MR; Chung DY; Simoyan OM; Davis CS; Nichols SD; McCall KL; Piper BJ
Pharmacoepidemiol Drug Saf; 2020 Jun; 29(6):708-715. PubMed ID: 32173955
[TBL] [Abstract][Full Text] [Related]
19. Do benefits restrictions limit Medicaid acceptance in addiction treatment? Results from a national study.
Andrews CM; Grogan CM; Westlake MA; Abraham AJ; Pollack HA; D'Aunno TA; Friedmann PD
J Subst Abuse Treat; 2018 Apr; 87():50-55. PubMed ID: 29471926
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
